The latest European Guidelines of Arterial Hypertension have officially introduced uric acid evaluation among the cardiovascular risk factors that should be evaluated in order to stratify patient's risk. In fact, it has been extensively evaluated and demonstrated to be an independent predictor not only of all-cause and cardiovascular mortality, but also of myocardial infraction, stroke and heart failure. Despite the large number of studies on this topic, an important open question that still need to be answered is the identification of a cardiovascular uric acid cut-off value. The actual hyperuricemia cut-off (> 6 mg/dL in women and 7 mg/dL in men) is principally based on the saturation point of uric acid but previous evidence suggests that the negative impact of cardiovascular system could occur also at lower levels. In this context, the Working Group on uric acid and CV risk of the Italian Society of Hypertension has designed the Uric acid Right for heArt Health project. The primary objective of this project is to define the level of uricemia above which the independent risk of CV disease may increase in a significantly manner. In this review we will summarize the first results obtained and describe the further planned analysis.

Hyperuricemia and Risk of Cardiovascular Outcomes. The Experience of the URRAH (Uric Acid Right for Heart Health) Project / Maloberti, Alessandro; Giannattasio, C; Bombelli, M; Desideri, G; Cicero, A F G; Muiesan, M L; Rosei, E A; Salvetti, M; Ungar, A; Rivasi, G; Pontremoli, R; Viazzi, F; Facchetti, R; Ferri, C; Bernardino, B; Galletti, F; D'Elia, L; Palatini, P; Casiglia, E; Tikhonoff, V; Barbagallo, C M; Verdecchia, P; Masi, S; Mallamaci, F; Cirillo, M; Rattazzi, M; Pauletto, P; Cirillo, P; Gesualdo, L; Mazza, A; Volpe, M; Tocci, G; Iaccarino, G; Nazzaro, P; Lippa, L; Parati, G; Dell'Oro, R; Quarti-Trevano, F; Grassi, G; Virdis, A; Borghi, C. - In: HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION. - ISSN 1120-9879. - 27:2(2020), pp. 121-128. [10.1007/s40292-020-00368-z]

Hyperuricemia and Risk of Cardiovascular Outcomes. The Experience of the URRAH (Uric Acid Right for Heart Health) Project

Desideri, G;Volpe, M;Tocci, G;
2020

Abstract

The latest European Guidelines of Arterial Hypertension have officially introduced uric acid evaluation among the cardiovascular risk factors that should be evaluated in order to stratify patient's risk. In fact, it has been extensively evaluated and demonstrated to be an independent predictor not only of all-cause and cardiovascular mortality, but also of myocardial infraction, stroke and heart failure. Despite the large number of studies on this topic, an important open question that still need to be answered is the identification of a cardiovascular uric acid cut-off value. The actual hyperuricemia cut-off (> 6 mg/dL in women and 7 mg/dL in men) is principally based on the saturation point of uric acid but previous evidence suggests that the negative impact of cardiovascular system could occur also at lower levels. In this context, the Working Group on uric acid and CV risk of the Italian Society of Hypertension has designed the Uric acid Right for heArt Health project. The primary objective of this project is to define the level of uricemia above which the independent risk of CV disease may increase in a significantly manner. In this review we will summarize the first results obtained and describe the further planned analysis.
2020
cardiovascular events; cardiovascular mortality; urrah; uric acid
01 Pubblicazione su rivista::01a Articolo in rivista
Hyperuricemia and Risk of Cardiovascular Outcomes. The Experience of the URRAH (Uric Acid Right for Heart Health) Project / Maloberti, Alessandro; Giannattasio, C; Bombelli, M; Desideri, G; Cicero, A F G; Muiesan, M L; Rosei, E A; Salvetti, M; Ungar, A; Rivasi, G; Pontremoli, R; Viazzi, F; Facchetti, R; Ferri, C; Bernardino, B; Galletti, F; D'Elia, L; Palatini, P; Casiglia, E; Tikhonoff, V; Barbagallo, C M; Verdecchia, P; Masi, S; Mallamaci, F; Cirillo, M; Rattazzi, M; Pauletto, P; Cirillo, P; Gesualdo, L; Mazza, A; Volpe, M; Tocci, G; Iaccarino, G; Nazzaro, P; Lippa, L; Parati, G; Dell'Oro, R; Quarti-Trevano, F; Grassi, G; Virdis, A; Borghi, C. - In: HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION. - ISSN 1120-9879. - 27:2(2020), pp. 121-128. [10.1007/s40292-020-00368-z]
File allegati a questo prodotto
File Dimensione Formato  
Maloberti_Hyperuricemia_2020.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.46 MB
Formato Adobe PDF
1.46 MB Adobe PDF   Contatta l'autore
Maloberti_Hyperuricemia_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 3.88 MB
Formato Adobe PDF
3.88 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1374582
Citazioni
  • ???jsp.display-item.citation.pmc??? 35
  • Scopus 109
  • ???jsp.display-item.citation.isi??? 89
social impact